IRIS PubliCatt
PubliCatt è il repository istituzionale ad accesso aperto dell'Università Cattolica del Sacro Cuore, dove gli utenti autorizzati afferenti all'Ateneo provvedono direttamente e autonomamente a depositare e a rendere visibili le proprie pubblicazioni, inserendo i dati descrittivi del documento stesso ("metadati", quali il titolo, autore, abstract, etc.) e, laddove possibile, il testo della pubblicazione stessa (full-text).
PubliCatt utilizza la piattaforma IRIS (Institutional Research Information System) sviluppata da CINECA.
English1. Monotherapy with mitotane is recommended in patients after incomplete surgical resection or in patients not fit for surgery or chemotherapy 1 ⊕⊕OO. 2. Monotherapy with mitotane may be recommended in advanced ACC with involvement of few organs and low-grade mitotic index, particularly when RFS after removal of the primary tumor has been longer than 12 months 1 ⊕OOOO. 3. The chemotherapeutic regimen EDP in combination with mitotane is recommended in most patients with advanced or metastatic ACC 1 ⊕⊕⊕⊕. 4. There are insufficient data to recommend a particular targeted therapy in patients with advanced ACC beyond ongoing clinical trials.
Stigliano, A., Chiodini, I., Giordano, R., Faggiano, A., Canu, L., Della Casa, S., Loli, P., Luconi, M., Mantero, F., Terzolo, M., Management of adrenocortical carcinoma: A consensus statement of the Italian Society of Endocrinology (SIE), <<JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION>>, 2016; 39 (1): 103-121. [doi:10.1007/s40618-015-0349-9] [http://hdl.handle.net/10807/172173]
| Autori: | ||
| Titolo: | Management of adrenocortical carcinoma: A consensus statement of the Italian Society of Endocrinology (SIE) | |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1007/s40618-015-0349-9 | |
| Data di pubblicazione: | 2016 | |
| Abstract: | 1. Monotherapy with mitotane is recommended in patients after incomplete surgical resection or in patients not fit for surgery or chemotherapy 1 ⊕⊕OO. 2. Monotherapy with mitotane may be recommended in advanced ACC with involvement of few organs and low-grade mitotic index, particularly when RFS after removal of the primary tumor has been longer than 12 months 1 ⊕OOOO. 3. The chemotherapeutic regimen EDP in combination with mitotane is recommended in most patients with advanced or metastatic ACC 1 ⊕⊕⊕⊕. 4. There are insufficient data to recommend a particular targeted therapy in patients with advanced ACC beyond ongoing clinical trials. | |
| Lingua: | Inglese | |
| Rivista: | ||
| Citazione: | Stigliano, A., Chiodini, I., Giordano, R., Faggiano, A., Canu, L., Della Casa, S., Loli, P., Luconi, M., Mantero, F., Terzolo, M., Management of adrenocortical carcinoma: A consensus statement of the Italian Society of Endocrinology (SIE), <<JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION>>, 2016; 39 (1): 103-121. [doi:10.1007/s40618-015-0349-9] [http://hdl.handle.net/10807/172173] | |
| Appare nelle tipologie: | Articolo in rivista, Nota a sentenza |
File in questo prodotto:
| File | Descrizione | Tipologia | Note | Licenza | |
|---|---|---|---|---|---|
| 172173.pdf | Versione Editoriale (PDF) | Nessuna Nota | Non specificato | Administrator |
Copyright © 2022